Navigation Links
Generex Common Stock to be Quoted on the OTCQB Under the Symbol 'GNBT' Beginning Thursday, October 21, 2010
Date:10/19/2010

WORCESTER, Mass., Oct. 19 /PRNewswire-FirstCall/ -- Generex Biotechnology Corporation (www.generex.com) announced today that on October 19, 2010 the NASDAQ Listing Qualifications Panel notified the Company that the Panel has determined to delist the Company's common stock from the NASDAQ Capital Market and will suspend trading of the stock effective at the open of trading on Thursday, October 21, 2010 as a consequence of the Company's non-compliance with NASDAQ's minimum $1.00 per share closing bid price requirement.

The Company has been advised by Pink OTC Markets Inc., which operates an electronic quotation service for securities traded over-the-counter (OTC), that the Company's common stock is immediately eligible for quotation on the OTCQB effective with the opening of the markets on October 21, 2010.  The OTCQB is a market tier for OTC traded companies that are registered and reporting with the Securities and Exchange Commission.  The Company has also been advised that its common stock will continue to trade under the symbol "GNBT".  Investors will be able to view real time stock quotes for GNBT at http://www.otcmarkets.com.

In September, 2010, there were 3,871 securities quoted on the OTCQB and the aggregate dollar value traded was just under $4 billion.

Generex management and its Board of Directors remain fully committed to the aggressive pursuit of the Company's product development and commercialization initiatives.  "The move to the OTCQB is not reflective of the value and tremendous potential of our pipeline," said Mark Fletcher, the Generex Interim President & Chief Executive Officer.  "Our efforts to move our pipeline products forward to commercialization will continue unabated."

At the reconvened Special Meeting of the Company's stockholders held on October 18, 2010, the reverse stock split proposal put forward by t
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
2. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
3. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
4. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
5. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
6. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
7. deCODE Discovers Major Genetic Risk Factor for the Most Common Form of Glaucoma
8. Delcath Systems Announces the Sale of 5,185,000 Shares of Common Stock
9. PDL BioPharma Announces Retirement of $61.6 Million of 2.75% Convertible Notes due August 2023 for Common Stock
10. Advanced Life Sciences CEO Acquires $2 Million of Common Stock Through Debt for Equity Exchange
11. DATATRAK Completes Sale of 357,857 Common Shares to Directors and Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 E-QURE Corp. (OTCQB: ... its Bio-electrical Signal Therapy device ("BST Device"), a new ... to heal chronic wounds, today announced that the Company ... Israeli distributor specializing in medical devices, for the marketing ... is a 70 years old, sales, marketing and distribution ...
(Date:8/3/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), ... of autologous cell therapies, announced today that RepliCel,s CEO, ... held in Minneapolis, Minnesota on August ... will highlight RepliCel,s 18-month milestones including CE Mark for its ... , clinical data from both RCT-01 (tendon) and RCS-01 (skin) ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... market analysis and premium industry insights on the global resorcinol industry. The report ... collective study of vivid market scenarios and analysis of primary and secondary inputs ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... Scientists from the University of Pennsylvania have developed ... years and retrieving that data a thousand times ... Flash memory and micro-drives, all using less power ... an assistant professor in the Department of Materials ...
... Sept. 17 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ... developing, manufacturing and marketing biopharmaceutical,products, will present at ... on Tuesday, September 25, 2007 at 10:30 AM ... and can be accessed on the Events,section of ...
... Bermuda, Sept. 17 Warner Chilcott,Limited (Nasdaq: WCRX ... a non-final Action Closing Prosecution from the U.S. Patent ... ordered a,reexamination of LEO,s US Patent No. 6,753,013 (the ... R&D. The 013 Patent covers TACLONEX,and certain of LEO,s ...
Cached Biology Technology:Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
(Date:7/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), ... the launch of a study that aims to ... (PCM) technology for predicting response to treatment in ... of the novel immunotherapy agents Yervoy® (ipilumumab), a ... The 50-patient study will be led by researchers ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
(Date:6/30/2015)... , June 30, 2015 To bolster its ... provider HYPR Corp. announced today the addition of two new ... serve as board advisor and David Raviv will ... team underscore HYPR Corp.,s commitment to providing the most secure ... Dimitri Sirota co-founded Layer 7 Technologies, a provider of ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... articles in the Society of Interventional Radiology,s flagship publication, ... report on studies related to peripheral arterial disease or ... Month. In one study, researchers determined that Framingham Risk ... cardiovascular risk) alone may not be enough to definitively ...
... new physics-based theory could give researchers a deeper understanding ... large polymers. This advance provides a better picture of ... for plastics and other polymeric materials. Kenneth S. ... materials science and engineering at the University of Illinois, ...
... landmark Cleveland institutions have come together to launch a ... sclerosis (MS). Researchers at the Cleveland Clinic, University Hospitals ... on a ground-breaking study that will test the feasibility ... to treat MS. In patients with MS, the ...
Cached Biology News:Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 3Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 4Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 5New theory may shed light on dynamics of large-polymer liquids 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 2Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 3Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 4Cleveland researchers collaborate to launch Phase 1 clinical trial for new MS treatment 5
... The NEW HandyStep electronic from ... repeat pipetting. It is the only ... most standard syringe tips, including BRAND ... Combi-Tips Plus, Fisherbrand Dispenser Tips,and VWRbrand ...
... can be used for efficient, mild and ... for ELISA or other assays for protein ... are bound with high efficiency to the ... will not elute during the assay due ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
The E. coli Expression System with Gateway Technology is designed to create E. coli expression clones containing the T7 promoter. The expression clones are ready for transformation and expression in ...
Biology Products: